1. Home
  2. MDWD vs FINW Comparison

MDWD vs FINW Comparison

Compare MDWD & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • FINW
  • Stock Information
  • Founded
  • MDWD 2000
  • FINW 1999
  • Country
  • MDWD Israel
  • FINW United States
  • Employees
  • MDWD N/A
  • FINW N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • FINW Commercial Banks
  • Sector
  • MDWD Health Care
  • FINW Finance
  • Exchange
  • MDWD Nasdaq
  • FINW Nasdaq
  • Market Cap
  • MDWD 184.8M
  • FINW 212.8M
  • IPO Year
  • MDWD 2014
  • FINW 2021
  • Fundamental
  • Price
  • MDWD $19.02
  • FINW $15.33
  • Analyst Decision
  • MDWD Strong Buy
  • FINW Buy
  • Analyst Count
  • MDWD 1
  • FINW 3
  • Target Price
  • MDWD $25.00
  • FINW $18.67
  • AVG Volume (30 Days)
  • MDWD 61.7K
  • FINW 19.3K
  • Earning Date
  • MDWD 11-26-2024
  • FINW 01-30-2025
  • Dividend Yield
  • MDWD N/A
  • FINW N/A
  • EPS Growth
  • MDWD N/A
  • FINW N/A
  • EPS
  • MDWD N/A
  • FINW 1.06
  • Revenue
  • MDWD $19,720,000.00
  • FINW $69,509,000.00
  • Revenue This Year
  • MDWD $10.37
  • FINW N/A
  • Revenue Next Year
  • MDWD $26.36
  • FINW $10.13
  • P/E Ratio
  • MDWD N/A
  • FINW $14.71
  • Revenue Growth
  • MDWD N/A
  • FINW 4.87
  • 52 Week Low
  • MDWD $11.04
  • FINW $8.72
  • 52 Week High
  • MDWD $24.00
  • FINW $20.50
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 61.79
  • FINW 35.07
  • Support Level
  • MDWD $15.80
  • FINW $15.51
  • Resistance Level
  • MDWD $18.25
  • FINW $16.65
  • Average True Range (ATR)
  • MDWD 0.88
  • FINW 0.71
  • MACD
  • MDWD 0.07
  • FINW -0.07
  • Stochastic Oscillator
  • MDWD 95.27
  • FINW 0.00

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About FINW FinWise Bancorp

FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.

Share on Social Networks: